The purpose of this study is to determine if an investigational medication taken by mouth, called zasocitinib, is safe and works better than deucravacitinib for patients who have moderate to severe plaque psoriasis.
Thank you for your interest, but this study will start enrolling soon.
North Carolina (Statewide)
Laura Ferris
Dermatology-Research
Clinical or Medical
Interventional
Skin, Hair, and Nails
25-0871
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
